The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML-Reference-Cited by-同舟云学术

The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML

Published:2019-01-08 Issue:8 Volume:234 Page:14040-14049
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Nguyen Le Xuan Truong¹²^ORCID,Troadec Estelle¹,Kalvala Arjun¹,Kumar Bijender¹,Hoang Dinh Hoa¹,Viola Domenico¹,Zhang Bin¹,Nguyen Dang Quan²,Aldoss Ibrahim³,Ghoda Lucy¹,Budde Elizabeth³,Pichiorri Flavia¹,Rosen Steven³⁴,Forman Stephen J.³⁴,Marcucci Guido¹³⁴,Pullarkat Vinod¹³⁴

Affiliation:

1. Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center Duarte California

2. Department of Medical Biotechnology Biotechnology Center of Ho Chi Minh City Ho Chi Minh City Vietnam

3. Department of Hematology and Hematopoietic Cell Transplantation City of Hope Medical Center Duarte California

4. City of Hope Comprehensive Cancer Center and Beckman Research Institute Duarte California

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.28091

Reference26 articles.

1. Superoxide-mediated proteasomal degradation of Bcl-2 determines cell susceptibility to Cr(VI)-induced apoptosis

2. The cytoprotective role of the Keap1–Nrf2 pathway

3. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

4. Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway

5. Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS regulator

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance;International Journal of Molecular Sciences;2023-12-29

2. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival;American Journal of Hematology;2023-12-15

3. Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress;Blood Advances;2023-12-13

4. Venetoclax in adult acute myeloid leukemia;Biomedicine & Pharmacotherapy;2023-12

5. Targeting the NF-E2-related factor 2 pathway for overcoming leukemia;International Journal of Biological Macromolecules;2023-12